What Happened?
Houston, TX-based Cellenkos Incorporated Appointed Elizabeth Read as Chief Technology Officer
About the Company
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.
About the Person
Elizabeth Read is Chief Technology Officer at Cellenkos Incorporated. Previously, Elizabeth held various senior IT leadership roles in the industry.
Info Source
News
Short Profile